Product Overview
The simplicity of one dose, once daily to help lower HbA1c in your adult T2D patients.1
Trajenta® contains the active ingredient linagliptin, which is a dipeptidyl peptidase-4 inhibitor (DPP-4i).1 Trajenta® is indicated in adults with type 2 diabetes mellitus (T2D) as an adjunct to diet and exercise to improve glycaemic control as:1
monotherapy when it is not appropriate to use metformin due to intolerance or contraindication as the result of renal impairment
combination therapy when other products, including insulin alone or in combination with metformin, do not provide sufficient glycaemic control
See SmPC for available information on different combinations.
Product key facts
Type 2 diabetes mellitis in adults
Linagliptin
Prescription only medicine
5 mg once a day
Oral
Film-coated tablet
Perforated alu/alu unit dose blisters in cartons containing 10 x 1, 14 x 1, 28 x 1, 30 x 1, 56 x 1, 60 x 1, 84 x 1, 90 x 1, 98 x 1, 100 x 1 and 120 x 1 film-coated tablets. Not all pack sizes may be marketed
Simple dosing for a broad range of adult patients
A broad range of adults with T2D§ can benefit from Trajenta®
Footnotes
-
*
Pharmacokinetic studies suggest that no dose adjustment is required for patients with hepatic impairment but clinical experience in such patients is lacking (Trajenta® SmPC).
-
†
Sulphonylureas and insulin are known to cause hypoglycaemia. Therefore, caution is advised when linagliptin is used in combination with a sulphonylurea and/or insulin. A dose reduction of the sulphonylurea or insulin may be considered (Trajenta® SmPC).
-
#
CARMELINA® and CAROLINA® included 6,979 and 6,033 patients respectively.7,8 Primary endpoint for these trials: Time to first occurrence of any of the following CV components: CV death (including fatal stroke and fatal MI), non-fatal MI (excluding silent MI), or non-fatal stroke (3P-MACE).8
-
§
Trajenta® is indicated in adults with type 2 diabetes mellitus as an adjunct to diet and exercise to improve glycaemic control as: monotherapy, when metformin is inappropriate due to intolerance, or contraindicated due to renal impairment; combination therapy, in combination with other medicinal products for the treatment of diabetes, including insulin, when these do not provide adequate glycaemic control.
Abbreviations:
3P-MACE: 3-point major adverse cardiac events; BMI: body mass index; CVOT: cardiovascular outcome trial; MI: myocardial infarction; SmPC: Summary of Product Characteristics; T2D: type 2 diabetes.
References
- Trajenta® (linagliptin) Summary of Product Characteristics. SmPCs available at EMC.
- Lajara R, et al. Clin Ther. 2014;36(11):1595-605.
- Del Prato S, et al. J Diab Compl. 2013;27:274–9.
- Cooper M, et al. Poster No. 1068-P. The 71st Scientific Sessions of the American Diabetes Association, 24–28 June 2011, San Diego, CA, USA.
- McGill JB, et al. Diabetes Care. 2013;36:237-44.
- Patel S, et al. European Association for the Study of Diabetes 2011, 12-16 September 2011, Lisbon, Portugal; Poster P832.
- Rosenstock J, et al. Cardiovasc Diabetol. 2018;17:39.
- Rosenstock J, et al. JAMA 2019; 321(1):69-79.
- Marx N, et al. Diab Vasc Res. 2015; 12:164-74.
- Rosenstock J, et al. JAMA. 2019;322(12):1155–1166.
Trajenta is indicated in adults with type 2 diabetes mellitus as an adjunct to diet and exercise to improve glycaemic control as:
monotherapy when metformin is inappropriate due to intolerance, or contraindicated due to renal impairment
in combination with other medicinal products for the treatment of diabetes, including insulin, when these do not provide adequate glycaemic control
PC-GB-110495 | December 2024